FRANKFURT, Germany (AP) — Danish pharmaceutical company Novo Nordisk A/S, maker of blockbuster weight loss drug Wegovy, said ...

Those who take tirzepatide, the drug sold as Zepbound and Mounjaro, could lose more weight than those who take semaglutide, ...

Eli Lilly said on Sunday its drug Zepbound was superior to Novo Nordisk's Wegovy across five weight-loss targets such as ...

In a 72-week trial, people taking Zepbound lost 50 pounds on average, compared with about 33 pounds for people taking Wegovy.

Clinical trial participants who took tirzepatide, the drug sold as Zepbound, lost an average of 50 pounds (22.8 kilograms) over 72 weeks, while those who took semaglutide, or Wegovy, lost about 33 ...

The popular weight loss medications produced different results in patients who participated in a trial, and here’s what ...

A new study has found that people taking Eli Lilly's obesity drug Zepbound lost almost 50% more weight than those using Novo ...

CVS Caremark decided to stop offering Zepbound in favor of Wegovy for weight loss. It’s the latest example of limits imposed by insurance that disrupt treatments for patients. By Rebecca Robbins ...

One weight loss injection has been branded more effective than another, after scientists carry out the first ever ...

By the end of the trial, those who took Zepbound lost about 20% of their body weight on average, compared with a nearly 14% loss for those who took Wegovy. The tirzepatide group trimmed about 7 ...